Study of AAV-hSMN1 (Vesemnogene Lantuparvovec) Gene Therapy in Subjects With Progressive Spinal Muscular Atrophy
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Numbers of participants with adverse events (AEs), serious adverse events (SAEs)
研究概览
简要总结
This is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.
详细描述
Study duration per participant is approximately 25 months including an approximately 30-day screening/baseline period, an approximately 24-month study observation period including 1 treatment day, and an approximately 24-month follow-up period. Patients will be stratified in two groups, those < 24 months of age at time of dosing and those ≥ 24 months of age at time of dosing. This study will be conducted in 2 stages:
Stage 1: dose escalting study in children <24 months of age. Stage 2: the selecetd dose from Stage 1 in children ≥ 24 months of age.
Patients will be tested at baseline and return for follow-up visits twice a week through the first month post dose, and followed by visits at months 2, 3, 6 12, 18 and 24 post infusion. Unscheduled visits may occur if the investigator determines that they are necessary.
For patients enrolled from overseas, follow-up visits with patient's own paediatrician together with remote virtual visits are allowed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of SMA based on gene mutation analysis with bi-allelic survival motor neuron (SMN1) mutations (deletion or point mutations).
- •Patients or Parent(s)/legal guardian(s) willing and able to complete the informed consent process and comply with study procedures and visit schedule.
排除标准
- •Anti-AAV9 antibody titers >1:20 as determined by Enzyme-linked Immunosorbent Assay (ELISA) binding immunoassay.
- •Active viral infection (includes HIV or serology positive for hepatitis B or C).
- •Use of invasive ventilatory support (tracheotomy with positive pressure) or pulse oximetry <95% saturation.
- •Concomitant illness and any drug that in the opinion of the investigator creates unnecessary risks for gene transfer.
- •Clinically significant abnormal laboratory values.
- •Participation in a recent SMA treatment clinical trial that in the opinion of the PI creates unnecessary risks for gene transfer.
- •Patient with signs of aspiration based on a swallowing test and unwilling to use an alternative method to oral feeding.
- •For children ≥ 24 months of age, contraindications for spinal tap procedure or administration of intrathecal therapy or presence of an implanted shunt for the drainage of CSF or an implanted central venous (CNS) catheter.
- •For children ≥ 24 months of age, severe contractures as determined by Physical Therapist(s) at screening that interfere with either the ability to attain/demonstrate functional measures or interferes with ability to receive dosing.
- •For children ≥ 24 months of age, severe scoliosis (defined as ≥ 50° curvature of spine) evident on X-ray examination.
- •For children ≥ 24 months of age, previous, planned or expected scoliosis repair surgery/procedure within 1 year of dose administration.
研究组 & 干预措施
Stage 1: Dose A in children < 24 months of age
Dose escalting study: Administration Dose A of Vesemnogene Lantuparvovec in children < 24 months of age
干预措施: vesemnogene lantuparvovec (Biological)
Stage 1: Dose B in children < 24 months of age
Dose escalting study: Administration Dose B of Vesemnogene Lantuparvovec in children < 24 months of age
干预措施: vesemnogene lantuparvovec (Biological)
Stage 2: The selected dose in children ≥ 24 months of age
Administration the selected dose of Vesemnogene Lantuparvovec in children ≥ 24 months of age
干预措施: vesemnogene lantuparvovec (Biological)
结局指标
主要结局
Numbers of participants with adverse events (AEs), serious adverse events (SAEs)
时间窗: Baseline up to 24 months
Participants are monitored for safety from baseline up to the end of the follow-up period.
次要结局
- Change from baseline in developmental gross motor milestones achieved according to WHO criteria(Baseline up to 24 months)
- Change from baseline in CHOP-INTEND in children <24 months of age(Baseline up to 24 months)
- Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) in children ≥ 24 months of age(Baseline up to 24 months)